Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
M&A activity
confidence 95%
filed 2026-05-27
Item 1.01
This disclosure describes the entry into multiple definitive material agreements on May 27, 2026, centered on a $1.268 billion asset-backed securitization transaction. NMAC transferred retail motor-vehicle installment sales contracts (Receivables) to NARC II, which then transferred them to the Issuing Entity, resulting in the issuance of $1.268 billion in asset-backed notes sold to major underwriters. This constitutes a material acquisition and disposition of assets with significant financial impact, fitting the ma_activity classification under Item 1.01.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-27
Item 2.03
The filing discloses issuance of $90 million in First Mortgage Bonds ($35M at 5.91% due 2036 and $55M at 6.65% due 2056) pursuant to Item 2.03. While this creates a direct financial obligation, it is a routine debt issuance by a utility company rather than a covenant breach, going-concern issue, or other acute financial stress signal. The bonds were issued to institutional investors in reliance on Section 4(a)(2) exemption and are secured by the company's mortgage. This is material to investors but does not fit the more specific event categories (covenant_breach, going_concern, bankruptcy_filing, etc.) and is best classified as other_material.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-27
Item 3.02
EQT Infrastructure Company LLC disclosed unregistered sales of equity securities totaling approximately $89.8 million in Investor Shares (Class A-I, A-S, M-I, and M-S) as of May 1, 2026, plus an additional issuance of approximately 239,536 Class E Shares valued at ~$6.6 million to EQT Holdings AB on May 26, 2026. Both offerings were exempt from registration under Section 4(a)(2) and Regulations D and S. The filing explicitly states this is part of a continuous private offering that has raised approximately $539.6 million since inception on February 1, 2026, representing a material capital raise through unregistered equity issuances.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-27
Item 3.02
EQT Private Equity Company LLC disclosed unregistered sales of equity securities totaling approximately $28.9 million in Investor Shares (Classes A-I, A-J1, A-J2, A-S) and $58.1 million in Class E Shares to EQT Holdings AB, all exempt from registration under Section 4(a)(2) and Regulation D/S. This is a classic dilutive issuance disclosure under Item 3.02, representing continuous private offerings that have cumulatively raised approximately $746.2 million since inception in July 2025.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from Cytokinetics' Annual Meeting of Stockholders held on May 27, 2026. The filing reports voting outcomes for four proposals: election of three Class I directors (Kaye, Wierenga, Wysenski), approval of an amendment to the 2015 Employee Stock Purchase Plan, ratification of Ernst & Young LLP as independent auditor, and an advisory vote on executive compensation. All proposals passed with substantial majorities, making this a material disclosure of governance and shareholder approval outcomes.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
Geron Corp held its 2026 Annual Meeting of Stockholders on May 20, 2026, with shareholders voting on four proposals: election of three Class III directors, approval of an amendment to the 2018 Equity Incentive Plan increasing the share reserve by 4.5 million shares, an advisory vote on named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes on four matters: election of eight directors, ratification of PricewaterhouseCoopers LLP as independent auditor, amendment to the Employee Stock Purchase Plan authorizing 700,000 additional shares, and an advisory vote on executive compensation. All four proposals passed by majority vote. Shareholder vote results are material to investors as they confirm governance and compensation decisions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-27
Item 3.02
Stepstone Private Credit Fund LLC completed an unregistered sale of 5,680,855 LLC interests for $148.1 million pursuant to subscription agreements, relying on Section 4(a)(2), Regulation D, and/or Regulation S exemptions. This private placement raises material capital while diluting existing investors.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-27
Item 1.01
Q32 Bio entered into a securities purchase agreement to sell 6,725,000 shares of common stock and 150,000 pre-funded warrants to accredited investors for approximately $55 million in gross proceeds under a PIPE (private investment in public equity) transaction relying on Section 4(a)(2) exemption. The company plans to file a Registration Statement for resale of the securities.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-27
Item 7.01
The Company retracted a press release announcing entry into a credit facility for its credit card program and clarified that no such facility has been entered into. This is a material correction of a prior public statement that could have affected investor expectations about the Company's financing and operational capacity. While the retraction itself is a corrective disclosure rather than a new material event, the fact that a material misstatement was publicly issued and then retracted warrants disclosure as a material event affecting the total mix of information available to investors.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-05-27
Item 1.01
Aptevo entered into a material collaboration agreement with Niowave on May 25, 2026, involving joint development of a therapeutic product combining Aptevo's proprietary molecules (APVO455) and Niowave's radioisotopes (Actinium-225), coupled with a concurrent stock purchase agreement under which Niowave acquired 98,522 shares and 53,201 warrants for $500,000, with options for up to ~97,373 additional shares.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-27
Item 8.01
The Fund reported NAV per share of $22.39 as of April 30, 2026, aggregate NAV of $4.4 billion, portfolio fair value of $7.0 billion, and debt-to-equity leverage of 0.63x, while updating the status of ongoing public and private share offerings totaling approximately $4.8 billion in consideration to date.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-27
Item 8.01
The filing discloses issuance of $1.375 billion in Series 2026-A Senior Secured SAC Bonds by Appalachian Power Recovery Funding LLC on May 27, 2026, pursuant to an Indenture and Series Supplement. While this is a material debt issuance that would affect investor assessment of the registrant's capital structure and financial obligations, it does not fit cleanly into the M&A activity category (which focuses on acquisitions, dispositions, mergers, or changes of control) and is disclosed under Item 8.01 (Other Events) rather than Item 1.01 or 2.01. The event is material but lacks a more specific taxonomy match.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-05-27
Item 1.01
Oncor entered into a Junior Subordinated Indenture and issued €850 million (approximately US$974.3 million) of junior subordinated notes due 2056. The proceeds were used for general corporate purposes and commercial paper repayment, constituting a material financing event affecting the company's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-27
Item 3.02
North Haven Private Income Fund LLC completed an unregistered sale of approximately 231,644 Class S units for $4.19 million to accredited investors, relying on Section 4(a)(2) and Regulation D exemptions. This private placement represents a significant capital raise and dilution to existing unitholders.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-27
Item 7.01
The fund disclosed routine portfolio and distribution information, including a declared distribution of $0.1227 per unit, portfolio composition across 306 companies totaling $7.183 billion in par value, and estimated NAV of $3.25 billion as of April 30, 2026. This periodic Regulation FD disclosure provides material information to unitholders regarding fund performance and income.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-27
Item 3.02
Silver Point Private Credit Fund conducted an unregistered sale of 1,359,664 common shares for $36.4 million at $26.76 per share pursuant to subscription agreements, exempt under Section 4(a)(2) and Regulation D. This dilutive equity issuance increases share count and affects shareholder ownership.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-05-27
Item 1.01
Crescent Capital BDC Funding, LLC entered into the Ninth Amendment to its Loan and Security Agreement with Wells Fargo on May 21, 2026, increasing the facility size from $400.0 to $500.0 million, extending maturity to May 21, 2031, and adjusting pricing and fees. This material modification to the company's capital structure and financing arrangements affects investor assessment of liquidity and leverage.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-27
Item 8.01
The company issued $50 million in Tranche C Notes (5.97% due May 22, 2029) on May 22, 2026, and concurrently repaid $111.6 million of existing 5.00% unsecured notes. This debt refinancing activity is material to investors assessing the company's capital structure and leverage.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
Xerox held its 2026 Annual Meeting of shareholders on May 27, 2026, with all four proposals approved: election of nine directors, ratification of PricewaterhouseCoopers LLP as independent auditor, advisory approval of 2025 named executive officer compensation, and approval of an amendment to the 2024 Equity and Performance Incentive Plan increasing authorized shares by 15,000,000.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This Item 5.07 discloses the results of a special stockholder meeting held on May 26, 2026, where shareholders voted on three proposals, including approval of the proposed acquisition by Banco Santander. The filing provides detailed vote tallies showing that all three proposals were approved by the requisite vote, with the Transaction Proposal receiving 115,788,667 votes in favor versus 1,279,203 against. This is a material shareholder vote result directly tied to a major M&A transaction.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Primerica's 2026 annual stockholders' meeting held on May 21, 2026. The filing presents voting results for three proposals: election of nine directors (all approved by majority vote), an advisory Say-on-Pay vote (approved), and ratification of KPMG LLP as independent auditor (approved). These are routine but material shareholder votes that affect board composition and auditor appointment.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-05-27
Item 2.02
The filing discloses U-Haul's financial results for the quarter ended March 31, 2026 via a press release attached as Exhibit 99.1, filed under Item 2.02 (Results of Operations and Financial Condition). This is a standard quarterly earnings release, which is material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
Stockholders voted at the Annual Meeting on four matters: election of nine directors, approval of the 2026 Long-Term Incentive Plan, advisory vote on executive compensation, and ratification of Grant Thornton LLP as independent auditor. The filing presents detailed voting results including votes for, against, abstain, and broker non-votes for each matter.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-27
Item 3.02
North Haven Private Income Fund A LLC completed an unregistered sale of approximately 88,416 Class I units for $1.8 million to accredited investors, relying on Section 4(a)(2) and Regulation D exemptions. This private placement represents dilution to existing unitholders and capital raising activity.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-27
Item 7.01
The fund disclosed routine portfolio and distribution information as of April 30, 2026, including a declared distribution of $0.1406 per unit, portfolio composition across 185 companies, estimated net asset value of $311.8 million, and leverage metrics showing debt of $313.1 million against NAV of $311.8 million. While primarily administrative, the leverage and NAV metrics may be material to investors assessing fund performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-05-27
Item 2.02
Synopsys issued a press release on May 27, 2026 announcing financial results for its second fiscal quarter ended April 30, 2026. The disclosure explicitly states the press release is attached as Exhibit 99.1, which is the standard format for earnings releases filed under Item 2.02. Quarterly financial results are material to investors' assessment of the company's operational performance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
Apple Hospitality REIT held its Annual Meeting on May 22, 2026, with shareholder votes on the election of eight directors, ratification of KPMG LLP as independent auditor, and an advisory vote on named executive officer compensation.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-27
Item 8.01
The Board approved an extension of the share repurchase program through July 2027 with authorization for up to $242.5 million in repurchases, representing a material commitment of corporate resources and capital deployment strategy.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 93%
filed 2026-05-27
Item 5.02
Synopsys appointed Jesse Cohn to its Board of Directors effective June 1, 2026, pursuant to a Cooperation Agreement with Elliott Investment Management dated May 26, 2026. Mr. Cohn was also appointed to the Corporate Governance and Nominating Committee and received standard director compensation and indemnification arrangements.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This Item 5.07 disclosure reports the results of Nuvation Bio's 2026 Annual Meeting of Stockholders held on May 21, 2026, including voting outcomes for three proposals: election of directors (Robert B. Bazemore, Jr., Robert Mashal, M.D., and Kim Blickenstaff), ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents final vote tallies with FOR/AGAINST/WITHHELD/BROKER NON-VOTE counts for each proposal, which is the core disclosure required under Item 5.07.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-27
Item 1.01
Minerva Neurosciences entered into an at-the-market (ATM) offering agreement with Leerink Partners on May 27, 2026, authorizing the issuance and sale of up to $75.0 million in common stock shares under its S-3 registration statement.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-27
Item 8.01
Minerva announced a material modification to the Phase 3 C19 trial design for roluperidone, extending the relapse assessment phase from 40 weeks to 52 weeks following FDA feedback, which extends the expected timeline for relapse data delivery to H2 2028.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This is a clear disclosure of shareholder voting results from the 2026 Annual Meeting of Stockholders held on May 27, 2026, covering three proposals: election of six directors, ratification of the independent auditor (WithumSmith+Brown, PC), and an advisory vote on compensation vote frequency. The filing presents final vote tallies for each proposal, which is the core content of Item 5.07 disclosures.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-27
Item 3.02
LGAM Private Credit LLC sold approximately 394,562 Common Units for $7.7 million at $19.61 per unit pursuant to subscription agreements with unitholders, exempt from Securities Act registration under Regulation S and targeting non-U.S. persons.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-27
Item 7.01
The company disclosed material portfolio and financial updates including a declared distribution of $0.1389 per unit, portfolio composition across 145 companies with $664.1M par value, estimated NAV of $242.3M, and debt outstanding of $307.7M as of April 30, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 99%
filed 2026-05-27
Item 5.07
Quanta Services held its 2026 Annual Meeting of Stockholders on May 21, 2026, with voting results on the election of ten directors, an advisory vote on executive compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-05-27
Item 5.02
This Item 5.02(e) disclosure centers on stockholder approval of the 2026 Equity Compensation Plan and the grant of 2026 long-term incentive awards (performance-based and time-based RSUs) to five named executive officers: Thornberry, Kobell, Dickerson, Hoffman, and Ray. The filing details specific grant amounts, vesting schedules, performance metrics, and termination provisions—all hallmarks of executive compensation disclosure. This is material as it affects investor assessment of executive incentive alignment and potential dilution.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-05-27
Item 4.01
This Item 4.01 discloses the dismissal of Deloitte & Touche LLP as the independent registered public accounting firm effective May 22, 2026, and the appointment of CBIZ CPAs P.C. as the replacement auditor effective May 20, 2026. The filing explicitly states material weaknesses in internal control over financial reporting existed in fiscal years 2024 and 2025, which is a reportable event under Item 304(a)(1)(v) of Regulation S-K. This auditor change, coupled with the disclosure of material control weaknesses, is material to investors' assessment of the company's financial reporting quality and internal control environment.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Honeywell's Annual Meeting of Shareowners held on May 22, 2026. The filing presents voting results for five matters: election of 12 directors, advisory vote on named executive officer compensation, appointment of Deloitte & Touche LLP as independent accountants, approval of a reverse stock split proposal, and a shareholder proposal on written consent rights. All matters passed except the written consent proposal. These results are material to investors as they confirm board composition, auditor selection, and shareholder approval of key corporate governance and capital structure decisions.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-27
Item 8.01
JPMorgan Chase announced the redemption of 2,000,000 depositary shares representing Series KK Preferred Stock on June 1, 2026. While this is a material capital structure event affecting preferred shareholders, it does not fit neatly into the more specific event categories (it is not M&A, a covenant breach, dilutive issuance, or other defined types). The redemption is material to investors as it affects the composition of outstanding securities and preferred equity, but the disclosure is primarily administrative in nature—an exercise of optional redemption rights under existing governing documents.
View raw filing on EDGAR →
8-K
Covenant Breach
confidence 35%
filed 2026-05-27
Item 2.03
The filing discloses creation of a direct financial obligation under Item 2.03, specifically a new $11 million loan draw on May 26, 2026, under the Master Digital Currency Loan Agreement with Galaxy Digital LLC. However, the disclosure focuses on routine refinancing and extension of existing debt rather than a covenant breach or triggering event that accelerates obligations. The language describes orderly debt management (extending maturity dates through successive refinancings) without evidence of default, acceleration, or breach. This is more appropriately classified as a material debt obligation creation, but since no specific event type directly captures routine debt refinancing, covenant_breach is the closest fit among available categories, though confidence is low given the absence of breach language.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This Item 5.07 discloses the results of a special shareholder meeting held on May 27, 2026, where Stellar Bancorp shareholders voted on two proposals: (1) approval of the merger agreement with Prosperity Bancshares (approved with 39,209,984 votes for vs. 59,317 against), and (2) a non-binding advisory vote on merger-related executive compensation (not approved with 15,683,085 for vs. 23,385,406 against). The merger approval is material to investors as it represents a change of control transaction.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-27
Item 8.01
Kennametal announced a cash tender offer to repurchase its 4.625% Senior Notes due 2028, with pricing and final results disclosed on May 26, 2026. This represents a material debt management activity affecting the company's capital structure and financial obligations, but does not fit neatly into the more specific event categories (ma_activity applies to acquisitions/dispositions of business units, not debt repurchases). The tender offer is material to investors as it affects leverage and cash position.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This is a clear disclosure of shareholder voting results from FrontView REIT's 2026 Annual Meeting of Stockholders held on May 27, 2026. The filing reports final voting tallies for two proposals: (i) election of seven directors with vote counts for each nominee, and (ii) ratification of KPMG as independent auditor. This is a textbook Item 5.07 disclosure and is material as director elections and auditor ratification are fundamental governance matters affecting investor confidence.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-27
Item 8.01
National Fuel Gas Company disclosed the exercise of optional redemption rights for $300 million in 5.50% Notes due October 2026, with a redemption date of June 11, 2026. While this is a material debt management action affecting the company's capital structure and liquidity, it does not fit cleanly into the specific event categories (not a covenant breach, not a going-concern issue, not a restatement). The redemption is a routine but material corporate finance event that a reasonable investor would want to know about.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This Item 5.07 filing discloses the results of Willis Lease Finance Corporation's 2026 Annual Meeting of Stockholders held on May 26, 2026. The filing reports voting outcomes for five proposals: election of Stephen Jones as Class I Director, a three-for-one stock split proposal (adjourned to June 23, 2026), advisory approval of executive compensation, ratification of Grant Thornton LLP as auditor, and approval of meeting adjournment. These are standard shareholder vote results that materially inform investors about corporate governance and capital structure decisions.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-05-27
Item 1.01
Teleflex entered into a new Credit Agreement on May 26, 2026, refinancing its existing credit facility with a syndicate of major lenders. The agreement provides $2.2 billion in total commitments ($1.0B revolving, $500M term A-1, $700M term A-2) and is secured by substantially all company assets and subsidiary equity interests.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-05-27
Item 1.01
PennantPark entered into an underwriting agreement on May 27, 2026 to issue $100 million of 7.375% Notes due 2031, with an additional $15 million option. While this is technically a debt issuance rather than an equity offering, the disclosure centers on a material capital-raising transaction that would affect investor assessment of the company's capital structure and financial position. The company intends to use proceeds to repay revolving credit obligations and invest in portfolio companies, indicating material financing activity.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-27
Item 5.07
This is a clear disclosure of shareholder vote results from Zimmer Biomet's annual meeting held May 22, 2026, covering four proposals: director elections, auditor ratification, advisory compensation approval, and a shareholder proposal on board chair independence. The detailed vote tabulation for each proposal is the core content of Item 5.07, which is the standard Item for reporting shareholder meeting outcomes. The results are material to investors as they reflect shareholder governance decisions and approval of executive compensation.
View raw filing on EDGAR →